NCT01218789View on ClinicalTrials.gov

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 28, 2010

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Non 24 Hour Sleep Wake Disorder
Interventions
DRUG

tasimelteon

20 mg tasimelteon capsules, PO daily for 1 year

Trial Locations (7)

Unknown

Garches

Lille

Lyon

Montpellier

Paris

Rennes

Toulouse

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY